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Abstract Two lipid transfer proteins are active in human
plasma, cholesteryl ester transfer protein (CETP), and
phospholipid transfer protein (PLTP). Mice by nature do
not express CETP. Additional inactivation of the PLTP gene
resulted in reduced secretion of VLDL and subsequently in
decreased susceptibility to diet-induced atherosclerosis.
The aim of this study is to assess possible effects of differ-
ences in PLTP expression on VLDL secretion in mice that
are proficient in CETP and PLTP. We compared human
CETP transgenic (huCETPtg) mice with mice expressing
both human lipid transfer proteins (huCETPtg/huPLTPtg).
Plasma cholesterol in huCETPtg mice was 1.5-fold higher
compared with huCETPtg/huPLTPtg mice (
 
P
 
 
 

 
 0.001).
This difference was mostly due to a lower HDL level in the
huCETPtg/huPLTPtg mice, which subsequently could lead
to the somewhat decreased CETP activity and concentration
that was found in huCETPtg/huPLTPtg mice (
 
P 
 

 
 0.05).
PLTP activity was 2.8-fold increased in these animals (
 
P 
 

 
0.001). The human PLTP concentration was 5 
 

 
g/ml. Mod-
erate overexpression of PLTP resulted in a 1.5-fold higher
VLDL secretion compared with huCETPtg mice (
 
P
 
 
 
 
 
0.05).
The composition of nascent VLDL was similar in both
strains.  These results indicate that elevated PLTP activity
in huCETPtg mice results in an increase in VLDL secretion.
In addition, PLTP overexpression decreases plasma HDL
cholesterol as well as CETP.
 
—Lie, J., R. de Crom, T. van
Gent, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van
Tol.
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Phospholipid transfer protein (PLTP) is an important
modulator of plasma HDL levels, size, and composition (1–
5). HDL is considered to protect against atherosclerosis by
transporting cellular cholesterol from cells in the arterial
wall to the liver for further excretion via the bile, as well as by
exerting anti-inflammatory and anti-oxidant effects (6–8).
 
The role of PLTP in atherosclerosis was recently evalu-
ated in PLTP deficient mice (5). PLTP deficiency in hy-
perlipidemic mouse models resulted in decreased athero-
sclerosis. In vitro experiments with cultured hepatocytes
from PLTP deficient mice revealed a defect in VLDL se-
cretion. These effects on VLDL secretion provided an ex-
planation for the decreased atherosclerosis found in PLTP
deficient mice (5).
Earlier we reported anti-atherogenic properties in mice
overexpressing human PLTP (huPLTPtg). Despite lower
HDL levels, plasma from these mice is more effective in
preventing in vitro accumulation of cholesterol by macro-
phages and is able to generate more pre
 

 
-HDL (3, 9).
Studies in mice with adenovirus-mediated overexpression
of human PLTP showed similar effects on HDL subclass
distribution (10, 11).
Thus, depending on the metabolic setting, PLTP may
have anti- or pro-atherogenic properties that require
further investigation. Presently, we aimed to evaluate
whether VLDL secretion is affected by variations in PLTP
activity. For this purpose, we crossbred transgenic mice for
human CETP (huCETPtg) with huPLTPtg mice (9) and
obtained huCETPtg/huPLTPtg mice. These mice provide
a unique model to study the role of PLTP in VLDL metab-
olism in the presence of CETP, which by nature is the situ-
ation in humans. Plasma lipoproteins, plasma CETP, and
PLTP activities, as well as human CETP and human PLTP
mass were also measured to study the impact of PLTP in
huCETPtg mice.
METHODS
 
Breeding and treatment of transgenic mice
 
The huCETPtg mice were kindly provided by Dr. A. R. Tall
(Columbia University, New York) and are in C57BL6 background
(9). HuPLTPtg mice (3) were backcrossed to C57BL6 back-
ground for at least seven generations. Mice expressing both hu-
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man CETP and human PLTP (huCETPtg/huPLTPtg) were
obtained by crossbreeding homozygous huCETPtg with homozy-
gous huPLTPtg mice. Both transgenes have the natural flanking
sequences, including the native promoters. Female mice were
used in further experiments. Animals were housed under stan-
dard conditions with free access to water and regular chow diet.
After fasting overnight blood samples were collected from the
orbital plexus by using Vitrex™ sodium-heparinized micropipettes
(80 IU) (Modulohm A/S, Copenhagen, Denmark) and immedi-
ately stored on ice. Blood was centrifuged at 2700 rpm for 15 min
at 4
 

 
C. Plasma was either used directly or stored in small aliquots
at 
 

 
80 
 

 
C before analysis. All experiments were approved by insti-
tutional and national guidelines (protocol nr.120.99.05).
 
In vivo hepatic VLDL secretion and composition
 
VLDL secretion experiments were performed according to
Jong et al. (12). VLDL secretion was measured in overnight
fasted mice which were injected intravenously with 15% (w/v)
Triton WR1339 (Sigma, St Louis, MO) (500 mg/kg body weight)
dissolved in 0.9% NaCl. After injection of Triton WR1339, blood
samples were drawn at appropriate time points (up to 90 min)
and triglyceride content was measured as described below. The
triglyceride accumulation in plasma was linear during this time
period. Hepatic triglyceride secretion rate was calculated from
the slope of the line and expressed as 
 

 
mol/h per kg body
weight.
From the blood samples obtained at t 
 

 
 90 min after Triton
WR1339 administration, plasma was taken and centrifuged at d 
 

 
1.006 g/ml in a Beckman 42.2 Ti rotor (34,200 rpm, 3 h, 12
 

 
C).
The top fraction containing VLDL was isolated by tube slicing.
 
Quantification of plasma lipids and protein
 
Cholesterol was determined enzymatically with the Free Cho-
lesterol C kit no. 274-47109 (WAKO, Neuss, Germany) after hy-
drolysis of cholesteryl esters with cholesterol esterase from 
 
Candida
cylindracea
 
 (Boehringer, Mannheim, Germany). Triglycerides were
measured with the Sigma GPO-Trinder kit no.337-B (Sigma, St
Louis, MO) and free fatty acids were measured with the NEFA C kit
no. 994-75409 (WAKO, Neuss, Germany). Phospholipids were mea-
sured with the PAP150 kit from Bio Merieux (Lyon, France). Pro-
tein was measured with a modification of the Lowry assay (13).
 
Separation of plasma lipoproteins by gelfiltration
 
Plasma from transgenic mice was analyzed by gelfiltration on
two HR10/30 FPLC columns in tandem (Superdex 200 prep-
grade, Superose 6 prepgrade, Pharmacia Biotech., Uppsala, Swe-
den). The columns were equilibrated with 2 mM NaH
 
2
 
PO
 
4
 
/
Na
 
2
 
HPO
 
4
 
, pH 7.4 [containing 0.9% NaCl (w/v), 0.02% NaN
 
3
 
(w/v) and 5 mM EDTA]. Combined plasma samples from seven
to ten mice were passed through 0.45-
 

 
m filters from Millipore
S.A. (Molsheim, France), and 0.5 ml was subjected to gelfiltra-
tion. The columns were run at 4
 

 
C with a flow rate of 0.1 ml/
min. Fractions of 0.8 ml were collected. Recoveries were 
 

 
 90%
for all analyses.
 
Plasma activity assays
 
CETP and PLTP activity assays were performed according to
Speijer et al. (14) as described before (9). The activities are ex-
pressed as percentage of human reference pool plasma. One
hundred percent is equivalent to the following activities: CETP
215.6 nmol/ml/h; PLTP 13.9 
 

 
mol/ml/h.
 
Human CETP and human PLTP mass determinations
by ELISA
 
The CETP ELISA assay was essentially performed as described
by Mezdour et al. (15). CETP mass was measured by a two-site an-
 
tibody immunoassay using a combination of two specific mono-
clonal antibodies for CETP: TP1 and TP2 (Ottawa Heart Institute,
Canada), which are able to inhibit the transfer of cholesterylest-
ers as well as triglycerides and recognize a similar epitope local-
ized in the carboxyterminal region of the CETP molecule (16).
Both antibodies (10 
 

 
g/ml) were coated overnight by incuba-
tion in phosphate buffered saline (PBS, pH 7.4) at 4
 

 
C on mi-
crowell plates (Immunoplate MaxiSorp; Nunc, Roskilde, Den-
mark). After washing the plates five times with washing buffer
[PBS containing 6% (v/v) methanol and 0.2% (w/v) Thesit
(Boehringer, Mannheim, Germany], the plates were incubated
for 1 h at 37
 

 
C with PBS containing 1% of bovine serum albumin
(BSA; ICN, OH) to prevent non-specific binding. After incuba-
tion, the wells were washed five times and calibrated control
plasma or mouse plasma samples, diluted in assaybuffer
[washing buffer containing 1% (w/v) BSA], were added and
incubated for 2 h at 37
 

 
C. After washing five times, antibody
TP20 labeled with digoxigenine (Ottawa Heart Institute, Can-
ada) was added and the plates were incubated for 2 h at 37
 

 
C
followed by five times washing and incubation with a solution
containing anti-digoxigenine Fab fragments for another 2 h at
37
 

 
C. Then, after washing five times, a solution with anti-
digoxigenine coupled to peroxidase (Boehringer, Mannheim,
Germany) was added followed by incubation for 45 min at
37
 

 
C. Tetramethylbenzidine (TMB, Merck, Darmstadt, Ger-
many) was freshly prepared in DMSO (6 mg/ml). Five hun-
dred microliters of the TMB/DMSO solution and 3 
 

 
l of
H
 
2
 
O
 
2
 
 was added to 30 ml citrate buffer (35 mM, pH 5.5). One
hundred microliters of this TMB solution was added to the
wells after washing the plates five times. After 30 min, the re-
action was stopped by the addition of 100 
 

 
l 2 N H
 
2
 
SO
 
4
 
. Ab-
sorbance was read at 450 nm. The intra- and inter-assay coeffi-
cients of variation were 3.6% and 8.0% respectively. In the
present study CETP activity correlated with human CETP mass
(
 
r
 
 
 

 
 0.93, 
 
P
 
 
 

 
 0.001).
Human PLTP mass was measured with a sandwich-type ELISA
essentially as described previously (17) with minor modifications:
the washing buffer contained 6% methanol (v/v) with 0.2%
Thesit (w/v) (Boehringer, Mannheim, Germany) and 0.1% (w/
v) Tween 20. The substrate solution used and the absorbance
measurements were performed as described for the CETP mass
determination. PLTP antibodies and standards were a generous
gift from Dr. H. Hattori (BML incorporated, Saitama, Japan). In
the present study PLTP activity correlated with human PLTP
mass (
 
r
 
 
 

 
 0.84, 
 
P
 
 
 

 
 0.05).
 
Statistical analysis
 
Data are expressed as mean 
 
	
 
 SD. Differences between hu-
CETPtg mice and huCETPtg/huPLTPtg mice were analyzed by
two sample Wilcoxon rank-sum tests.
 
RESULTS
 
Plasma activities of CETP and PLTP
 
The activities of CETP and PLTP were measured in
plasma samples from huCETPtg mice and huCETPtg/hu-
PLTPtg mice. CETP activity was 1.15-fold higher in hu-
CETPtg mice compared with huCETPtg/huPLTPtg mice
(
 
P
 
 
 

 
 0.05) (
 
Table 1
 
). PLTP activity in plasma of hu-
CETPtg mice was equal to activity levels found in wild-type
mice (3). In huCETPtg/huPLTPtg mice PLTP activity was
2.8-fold higher (
 
P
 
 
 

 
 0.001).
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Lipoprotein analyses
 
Plasma samples from either huCETPtg or huCETPtg/
huPLTPtg mice were analyzed by gelfiltration chromatog-
raphy to examine their lipoprotein profiles. Phospholipid
contents as well as CETP and PLTP activities were deter-
mined in all fractions (
 
Fig. 1
 
). The HDL phospholipids in
huCETPtg/huPLTPtg mice show a decrease due to PLTP
overexpression (Fig. 1A). The phospholipids in fractions
20–25 represent lysophosphatidylcholine bound to albu-
min. A similar profile, apart from the peak in fractions
20–25, was obtained for cholesterol (not shown). CETP
activity eluted in fractions corresponding to the size of
HDL (Fig. 1B) and PLTP activity eluted in the fractions
9–15 corresponding with relatively large HDL particles
(Fig. 1C), a situation also found in humans (14).
 
Determination of human CETP and human
PLTP concentrations
 
Human CETP and human PLTP mass were analyzed in
the plasma of huCETPtg and huCETPtg/huPLTPtg mice.
CETP concentration was higher in huCETPtg mice com-
pared with huCETPtg/huPLTPtg mice (
 
P
 
 
 

 
 0.05). Human
CETP mass co-eluted with CETP activity in the lipoprotein
profiles of both huCETPtg and huCETPtg/huPLTPtg
mice (
 
Fig. 2A
 
,
 
 B
 
, respectively). PLTP concentration in hu-
CETPtg/huPLTPtg mice was 5.1 
 
	
 
 0.7 
 

 
g/ml. In hu-
CETPtg/huPLTPtg mice human PLTP mass co-eluted
with PLTP activity in the lipoprotein profile (Fig. 2C).
 
Cholesterol, triglyceride, and free fatty acid measurements
 
Before studying the influence of PLTP on VLDL metab-
olism, we measured cholesterol, triglyceride, and free fatty
acid content in plasma of huCETPtg mice and hu-
CETPtg/huPLTPtg mice. Plasma cholesterol in huCETPtg
mice was 1.5-fold higher than in huCETPtg/huPLTPtg
mice (
 
P
 
 
 

 
 0.001) (Table 1). The triglyceride and free fatty
acid levels were similar in both groups of mice (Table 1).
 
Effect of human PLTP on hepatic VLDL secretion
 
After intravenous injection of Triton WR1339, the rate
of plasma triglyceride accumulation was measured by de-
termining triglycerides in plasma at appropriate time
points (
 
Fig. 3A
 
). The triglyceride accumulation rates cal-
culated for each individual mouse were related to their
body weights. There was no difference in body weight be-
tween the mice from the two groups (huCETPtg mice
19.6 
 
	
 
 1.3 g; huCETPtg/huPLTPtg mice 19.2 
 
	
 
 0.9 g).
The secretion rate was calculated from the slope of the in-
dividual lines and is expressed as 
 

 
mol/kg/h. The VLDL
secretion rate was 1.5-fold higher in huCETPtg/huPLTPtg
mice. HuCETPtg mice showed a rate of 140 
 
	
 
 49 versus
 
TABLE 1. Plasma levels of lipids, CETP, and PLTP activities as well as 
human CETP and human PLTP concentrations in transgenic mice
 
n huCETPtg n  huCETPtg/huPLTPtg
 
Cholesterol (mM) 10 1.9
 
a
 
 
 
	
 
 0.3 11 1.3 
 
	
 
 0.1
Triglycerides (mM) 9 0.3 
 
	
 
 0.4 5 0.2 
 
	
 
 0.1
Free fatty acids (mM) 5 1.0 
 
	
 
 0.1 5 1.0 
 
	
 
 0.2
CETP activity (%) 12 126
 
b
 
 
 
	
 
 13 11 110 
 
	
 
 22
Human CETP (
 

 
g/ml) 6 4.4
 
b
 
 
 
	
 
 1.9 7 2.9 
 
	
 
 0.5
PLTP activity (%) 13 148
 
a
 
 
 
	
 
 24 11 418 
 
	
 
 54
Human PLTP (
 

 
g/ml) 4 ND 4 5.1 
 
	
 
 0.7
CETP and PLTP activities are expressed as percentage of human
reference pool plasma values (%). One hundred percent of the human
reference pool plasma is equivalent to a CETP activity of 215.6 nmol/
ml/h and to a PLTP activity of 13.9 
 

 
mol/ml/h. Differences between
huCETPtg mice and huCETPtg/huPLTPtg mice were analyzed by two
sample Wilcoxon rank-sum tests. Values are means 
 
	
 
 SD. n, individual
mouse plasma samples measured; ND, not detectable.
 
a 
 
P
 
 
 

 
 0.001.
 
b 
 
P
 
 
 

 
 0.05.
Fig. 1. Lipoprotein profiles of plasma from transgenic mice.
Equal amounts of plasma from either huCETPtg mice (n  7)
or huCETPtg/huPLTPtg mice (n  10) were pooled and sub-
jected to gel filtration on Superose 6 and Superdex 200 columns
connected in tandem as described in Methods. Fractions were
analyzed for (A) phospholipids and (B) CETP activity: 100% hu-
man reference pool plasma is equivalent to CETP activity of
215.6 nmol/ml/h. C: PLTP activity: 100% human reference
pool plasma is equivalent to PLTP activity of 13.9 mol/ml/h.
Fractions 1–5 contain VLDL; 6–11 contain LDL; 12–20 contain
HDL and 21–25; contain lysophosphatidylcholine bound to al-
bumin.
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208 	 41 mol/kg/h in huCETPtg/huPLTPtg mice (P 
0.05).
The chemical composition of VLDL was analyzed at 90
min after Triton WR1339 injection. The composition of
nascent VLDL (Fig. 3B) was similar in the two groups of
mice. Others have verified that catabolism of VLDL is
completely blocked by Triton WR1339 and therefore the
composition of the accumulated VLDL is a direct measure
of the composition of nascent VLDL (18).
DISCUSSION
The exact role of PLTP in lipoprotein metabolism is not
clear. Earlier studies have shown that PLTP has both anti-
and pro-atherogenic effects on lipoproteins (3, 5, 9). It
was demonstrated that mouse models lacking PLTP are
less prone to diet-induced atherosclerosis. In two out of
three models studied (5), this could be attributed to a re-
duced secretion of VLDL. PLTP deficiency or functional
gene polymorphisms have not been found in humans.
Moreover, unlike humans, mice do not have plasma CETP
activity (19). Thus, total deficiency of both CETP and
PLTP represent an extreme situation from which the ef-
fects on lipoprotein metabolism cannot be directly extrap-
olated to humans.
The purpose of the present study is to evaluate the in-
fluence of PLTP on VLDL metabolism in a mouse model
with appreciable CETP activity. In this study, we demon-
strate that elevated expression of PLTP increases hepatic
VLDL secretion in mice in the presence of human CETP
without affecting the composition of the secreted VLDL.
Fig. 2. Human CETP and PLTP concentrations with their corre-
sponding activities measured in gelfiltration fractions of plasma
from transgenic mice. A: Human CETP concentrations and CETP
activities in huCETPtg mice (n  7, r  0.99, P  0.001). B: Human
CETP concentrations and CETP activities in huCETPtg/huPLTPtg
mice (n  10, r  0.92, P  0.001). C: Human PLTP concentrations
and PLTP activities in huCETPtg/huPLTPtg mice (n  13, r 
0.97, P  0.001).
Fig. 3. In vivo hepatic VLDL secretion in transgenic mice. A: Tri-
glyceride production rates in transgenic mice were measured after
Triton WR1339 administration. HuCETPtg mice are represented by
open squares (n  7) and huCETPtg/huPLTPtg mice are repre-
sented by closed squares (n  6). Differences between huCETPtg
mice and huCETPtg/huPLTPtg mice were analyzed by two sample
Wilcoxon rank-sum tests. The lines represent the mean triglyceride
rates 	 SD of individual mice within huCETPtg and huCETPtg/hu-
PLTPtg mice (*P  0.05). B: Lipoprotein composition in nascent
VLDL. VLDL was isolated from transgenic mouse plasma 90 min af-
ter Triton WR1339 administration by density ultracentrifugation at
d  1.006 g/ml (34,200 rpm, 3 h, 12C). Lipids and protein were
determined and expressed in percentage of total weight. Black seg-
ments represent the percentage of triglycerides, hatched segments
represent the percentage of protein, white segments represent the
percentage of phospholipids and cross-hatched segments represent
the percentage of cholesterol in nascent VLDL.
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Despite the increase of VLDL secretion in the huCETPtg/
huPLTPtg mice, we did not observe an increase in plasma
VLDL levels. This may be due to an increased turnover of
VLDL, or to increased receptor-mediated uptake by the
liver. It is unlikely that the augmented VLDL secretion by
PLTP is caused by an increased provision of free fatty acids
from plasma to the liver, since no difference was found be-
tween the free fatty acid content in plasma of huCETPtg
and huCETPtg/huPLTPtg mice (Table 1). Additional ex-
periments showed that the elevation of VLDL secretion
can be specifically attributed to the PLTP transgene. Us-
ing mice solely transgenic for human PLTP, we observed a
1.6-fold increase in VLDL secretion, if compared to wild
type mice. As recently demonstrated (5), PLTP plays a
possible intracellular role in the liver. Because PLTP activ-
ity has been found in the Golgi, PLTP could be involved in
the process of adding lipids to nascent VLDL particles.
Plasma cholesterol content was 1.5-fold higher in hu-
CETPtg mice compared with huCETPtg/huPLTPtg mice
(Table 1). Thus, overexpression of human PLTP in hu-
CETPtg mice results in a decrease in total plasma choles-
terol, mostly due to HDL lowering, as HDL is the major
component of the plasma lipoproteins in mice. Raised
PLTP activity in other transgenic mouse models also give
rise to low HDL cholesterol levels (3, 10, 11). The de-
crease in plasma HDL is explained by an enhanced up-
take of HDL cholesteryl esters by the liver (10). Interest-
ingly, PLTP deficient mice also show markedly reduced
HDL, probably due to HDL hypercatabolism (20, 21).
Kawano et al. demonstrated that CETP overexpression
could not compensate PLTP deficiency and caused an ad-
ditional lowering of HDL (22).
Plasma CETP activity measured in huCETPtg mice is
higher than in huCETPtg/huPLTPtg mice (Table 1). The
lower CETP activity found in huCETPtg/huPLTPtg mice
may result from the lower plasma HDL concentrations
caused by PLTP overexpression (9). Because CETP is car-
ried on HDL (14), lower plasma HDL concentrations
could eventually give rise to lower CETP levels. The CETP
concentrations in both groups of mice (Table 1) are
within the range of human values, indicating that the
mouse models used resemble the human situation both in
terms of CETP activity and mass (23).
PLTP activity levels in plasma of huCETPtg were equal
to the activities found in wild-type mice (3). As expected,
PLTP activity was higher in huCETPtg/huPLTPtg mice
than in the huCETPtg mice (Table 1). The human PLTP
mass measured in huCETPtg/huPLTPtg mice is within
the range of reported plasma PLTP concentrations in hu-
mans (17, 24, 25). In contrast to what has been reported
in humans (26, 27), in our mice PLTP activity correlates
with human PLTP mass. In human plasma, such a correla-
tion is not found due to the presence of inactive PLTP
mass. In our studies, we found no evidence of inactive
forms of PLTP in mice, since PLTP activity and PLTP mass
elute in the same fractions in the lipoprotein profile (Fig.
2C). At present, the physiological importance, if any, of in-
active PLTP is unknown. Studies in humans showed that
type II diabetic patients have higher PLTP mass and activ-
ity compared with nondiabetic subjects (24, 28). In-
creased PLTP activity has also been reported in type I dia-
betic patients (29) and in the obese (30, 31). Both
diabetes and obesity have been associated with an in-
creased risk of coronary artery disease, indicating a possi-
ble pro-atherogenic potential for PLTP.
By comparing huCETPtg mice with huCETPtg/hu-
PLTPtg mice we observed that elevated PLTP leads to in-
creased hepatic VLDL secretion. This is in line with ex-
periments by Jiang et al. performed with cultured
hepatocytes isolated from PLTP deficient mice, which
showed a defect in VLDL secretion (5), and strengthens
their suggestion that PLTP has an intracellular function in
liver cells.
In the present study, we showed for the first time that el-
evation of plasma PLTP in transgenic mice increases
VLDL secretion. Concomitantly with increased VLDL se-
cretion, elevated PLTP resulted in lower levels of plasma
HDL, both effects resulting in a more atherogenic lipo-
protein profile. The huCETPtg/huPLTPtg mice used in
this study provide a unique model because it resembles
the human condition in terms of CETP activity and mass.
In future studies we will test the impact of PLTP overex-
pression on diet induced atherosclerosis in huCETPtg
mice.
This work was supported by the Dutch Heart Foundation grant
NHS 98.088. We thank Thijs van Aken for the assistance in the
in vivo hepatic VLDL secretion experiments.
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